Mesoblast Limited
MESO
$11.60
-$0.22-1.86%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -6.85% | -6.85% | -41.23% | -67.59% | -11.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.85% | -6.85% | -41.23% | -67.59% | -11.72% |
| Cost of Revenue | -183.56% | -183.56% | -29.71% | -59.29% | -74.81% |
| Gross Profit | 317.74% | 317.74% | 27.86% | 57.88% | 83.67% |
| SG&A Expenses | 49.70% | 49.70% | 6.79% | -52.61% | -10.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 104.76% | 104.76% | -63.51% | 100.60% | -110.98% |
| Total Operating Expenses | -22.79% | -22.79% | -20.11% | -48.05% | -31.10% |
| Operating Income | 24.83% | 24.83% | 17.74% | 45.42% | 32.97% |
| Income Before Tax | -46.20% | -46.20% | -26.39% | 25.58% | 33.54% |
| Income Tax Expenses | 307.84% | 307.84% | -11.25% | 51.63% | 28.17% |
| Earnings from Continuing Operations | -47.31% | -47.31% | -26.41% | 25.51% | 33.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.31% | -47.31% | -26.41% | 25.51% | 33.56% |
| EBIT | 24.83% | 24.83% | 17.74% | 45.42% | 32.97% |
| EBITDA | 26.02% | 26.02% | 17.72% | 44.64% | 33.39% |
| EPS Basic | -12.90% | -12.90% | -6.01% | 51.09% | 41.51% |
| Normalized Basic EPS | -3.48% | -3.48% | 17.31% | 61.95% | 45.75% |
| EPS Diluted | -12.90% | -12.90% | -6.01% | 51.19% | 41.51% |
| Normalized Diluted EPS | -3.48% | -3.48% | 17.31% | 61.95% | 45.75% |
| Average Basic Shares Outstanding | 30.49% | 30.49% | 19.11% | -23.84% | 13.61% |
| Average Diluted Shares Outstanding | 30.49% | 30.49% | 19.11% | -23.84% | 13.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
